CD137 (4-1BB/tnfrsf9) has been shown to co-stimulate T cells. However, agonistic anti-CD137 monoclonal antibody (mAb) treatment can suppress CD4 ＋ T cells, ameliorating autoimmune diseases, whereas it induces activation of CD8 ＋ T cells, resulting in diverse therapeutic activity in cancer, viral infection. To investigate the CD137-mediated T cell suppression mechanism, we examined whether anti-CD137 mAb treatment could affect CD11b through Ag-specific CD8 ＋ T cell activation while suppressing
Ag-specific CD4 ＋ T cells and antibody responses (5) that result in the amelioration of autoimmune diseases (6-10) and chronic graft versus host diseases (11) . In a recent study that aimed to clarify the mechanism of this phenomenon, Ag-dependent and CD137-mediated induction of a new cell population, CD11c
＋

CD8
＋ T cells, was identified in a rheumatoid arthritis model and was shown to be crucial for inducing suppression of Ag-specific CD4 ＋ T cells by interferon gamma (IFNγ) and indoleamine 2,3-dioxygenase (IDO) (9) . Furthermore, the emergence of CD11c ＋ CD8 ＋ T cells by anti-CD137 mAb treatment was also reported in other disease models, such as virus infection, experimental autoimmune uveoretinitis and tumors (12, 13) . However, the mechanisms responsible for the suppression mediated by anti-CD137 mAb treatment are still unclear. Therefore, to understand the suppressive outcomes of CD137 stimulation, the undefined changes in cell types and functions induced by anti-CD137 mAb treatment need to be further examined. A recent study showed that interactions between CD137 and CD137L have limited roles in myelopoiesis and the development of dendritic cells (14) , suggesting the possibility that CD137 signaling is involved in myeloid cell development and differentiation. Furthermore, it has been shown that in vivo anti-CD137 mAb treatment in a spontaneous lupus-like syndrome model induces the expansion of macrophage/granulocyte population in an IFNγ-dependent manner (6) . However, it is still unclear whether anti-CD137 mAb treatment af-IMMUNE NETWORK http://www.ksimm.or.kr Volume 10 Number 3 June 2010 treatment of anti-CD137 mAb and peaked at day 10 ( Fig. 2B) . Collectively, these data suggested that anti-CD137 mAb treatment could strongly induce the increase in CD11b obtained from naïve mice (Fig. 3A and B) . Furthermore, this suppressive activity was also shown in CD11b
isolated at 25 day after anti-CD137 mAb injection ( Fig. 3C and  D) . Collectively, we concluded that CD137 stimulation dramatically induced CD11b ＋ Gr-1 ＋ cells, which suppressed both CD8 ＋ and CD4 ＋ T cells.
In this study, we demonstrated that, for the first time, anti-CD137 mAb treatment significantly induced CD11b
MDSCs. The presence of this population might explain a novel mechanism of CD137 stimulation-mediated suppression of T cells. Thus, to thoroughly understand the diverse outcome of anti-CD137 mAb treatment, the nature of this population needs to be clarified more precisely.
We measured CD137 expression on naïve CD11b Likewise, it has been reported that surface expression of CD137 is absent on MDSCs (17) . We also checked the IFNγ dependency because IFNγ-dependent, anti-CD137-induced CD11b ＋ Gr-1 ＋ cell expansion was reported in autoimmune disease model (6) . However, under normal conditions this phenomenon was not found (data not shown). Thus, it seemed that CD137 stimulation indirectly affected CD11b ＋ Gr-1 ＋ cells by an IFNγ-independent pathway, and further studies are needed to define the mechanism of anti-CD137 mAb treatment on MDSC induction. MDSCs can suppress T cell proliferation and activation by secreting iNOS, arginase, reactive oxygen species, nitrating TCR and deprivating cysteine (16) . Future studies should investigate whether CD11b ＋ Gr-1 ＋ cells induced by CD137 signaling also use same suppression mechanisms as MDSCs or have a unique system. Although it was reported that anti-CD137 mAb-injected mice developed a series of immunological anomalies (15), preliminary results from ongoing clinical trials using the humanized anti-CD137 mAb in cancer patients showed that the toxicity profile in these patients was mild (18) . However, there is also the possibility that these newly revealed immunosuppressive CD11b 
